-+ 0.00%
-+ 0.00%
-+ 0.00%

Rocket Pharmaceuticals Q3 2026 Net Loss Narrows to $49.2 Million

PUBT·11/12/2026 21:01:55
Listen to the news
Rocket Pharmaceuticals Q3 2026 Net Loss Narrows to $49.2 Million
  • Rocket Pharmaceuticals’ third-quarter 2026 net loss narrowed to $49.2 million from a year earlier.
  • Quarterly research and development expenses fell 9% to $31.2 million, while general and administrative expenses rose 8% to $19.8 million.
  • Cash, cash equivalents and investments totaled $279.4 million at September 30, 2026, with operations funded into the third quarter of 2028.
  • RP-A501 pivotal trial dosing is expected to finish by mid-2027, with topline results anticipated in mid-2028.
  • KRESLADI reached commercial readiness October 1, 2026, with two Qualified Treatment Centers activated for commercial patient onboarding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611121600BIZWIRE_USPR_____20261112_BW164218) on November 12, 2026, and is solely responsible for the information contained therein.